News - Pfizer, Nephrology and Hepatology

Filter

Popular Filters

Pfizer's Torisel fails in Ph III advanced renal cell cancer study

17-05-2012

There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III…

BayerNephrology and HepatologyNexavarOncologyPfizerPharmaceuticalResearchTorisel

Robust growth forecast for renal cell carcinoma market

11-12-2011

The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

Back to top